X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease
- PMID: 8885720
- DOI: 10.1002/bies.950181009
X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease
Abstract
X-linked agammaglobulinemia is a heritable immunodeficiency disease caused by a differentiation abnormality, resulting in the virtual absence of B lymphocytes and plasma cells. The affected gene encodes a cytoplasmic protein tyrosine kinase, Bruton's agammaglobulinemia tyrosine kinase, designated Btk. Btk and the other family members, Tec, ltk and Bmx, contain five regions, four of which are common structural and functional modules that are found in other signaling proteins. Mutations affect all domains of the gene, but amino acid substitutions seem to be confined to certain regions. More than 150 unique mutations have been identified and are collected in a mutation database, BTKbase. Here we discuss the three-dimensional structural implications of such mutations and their putative functional role. Of special interest are mutations affecting the pleckstrin homology domain, as Btk is the only disease-associated protein so far reported to carry mutations in this particular module.
Similar articles
-
Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia.Hum Mutat. 1999;13(4):280-5. doi: 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L. Hum Mutat. 1999. PMID: 10220140
-
Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.Immunol Rev. 2005 Feb;203:200-15. doi: 10.1111/j.0105-2896.2005.00225.x. Immunol Rev. 2005. PMID: 15661031 Review.
-
Mutation analysis of the gene encoding Bruton's tyrosine kinase in a family with a sporadic case of X-linked agammaglobulinemia reveals three female carriers.Am J Med Genet. 1995 Nov 6;59(2):188-92. doi: 10.1002/ajmg.1320590214. Am J Med Genet. 1995. PMID: 8588584
-
Detection of a novel mutation in the SRC homology domain 2 (SH2) of Bruton's tyrosine kinase and direct female carrier evaluation in a family with X-linked agammaglobulinemia.Am J Med Genet. 1996 May 3;63(1):318-22. doi: 10.1002/(SICI)1096-8628(19960503)63:1<318::AID-AJMG53>3.0.CO;2-N. Am J Med Genet. 1996. PMID: 8723128
-
Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA).Front Biosci. 2000 Dec 1;5:D917-28. doi: 10.2741/vihinen. Front Biosci. 2000. PMID: 11102316 Review.
Cited by
-
Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia.J Clin Immunol. 2010 Jan;30(1):121-31. doi: 10.1007/s10875-009-9341-5. Epub 2009 Nov 11. J Clin Immunol. 2010. PMID: 19904586
-
BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia.Oncol Lett. 2024 Jul 4;28(3):424. doi: 10.3892/ol.2024.14557. eCollection 2024 Sep. Oncol Lett. 2024. PMID: 39021736 Free PMC article.
-
KinMutBase, a database of human disease-causing protein kinase mutations.Nucleic Acids Res. 2000 Jan 1;28(1):369-71. doi: 10.1093/nar/28.1.369. Nucleic Acids Res. 2000. PMID: 10592276 Free PMC article.
-
Kinase mutant Btk results in atypical X-linked agammaglobulinaemia phenotype.Clin Exp Immunol. 2000 May;120(2):346-50. doi: 10.1046/j.1365-2249.2000.01230.x. Clin Exp Immunol. 2000. PMID: 10792386 Free PMC article.
-
T cell immunity following COVID-19 vaccination in adult patients with primary antibody deficiency - a 22-month follow-up.Front Immunol. 2023 May 9;14:1146500. doi: 10.3389/fimmu.2023.1146500. eCollection 2023. Front Immunol. 2023. PMID: 37234151 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources